RU2496790C2 - Нейроэндокринные факторы для лечения дегенеративных заболеваний - Google Patents

Нейроэндокринные факторы для лечения дегенеративных заболеваний Download PDF

Info

Publication number
RU2496790C2
RU2496790C2 RU2010114713/10A RU2010114713A RU2496790C2 RU 2496790 C2 RU2496790 C2 RU 2496790C2 RU 2010114713/10 A RU2010114713/10 A RU 2010114713/10A RU 2010114713 A RU2010114713 A RU 2010114713A RU 2496790 C2 RU2496790 C2 RU 2496790C2
Authority
RU
Russia
Prior art keywords
cartilage
cells
pharmaceutical composition
slit3
growth
Prior art date
Application number
RU2010114713/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2010114713A (ru
Inventor
Аня БОССЕРХОФФ
Томас ШУБЕРТ
Элизабет ХУШТЕРТ
Original Assignee
Формикон Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07018131A external-priority patent/EP2036921A1/en
Application filed by Формикон Аг filed Critical Формикон Аг
Publication of RU2010114713A publication Critical patent/RU2010114713A/ru
Application granted granted Critical
Publication of RU2496790C2 publication Critical patent/RU2496790C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2010114713/10A 2007-09-14 2008-09-12 Нейроэндокринные факторы для лечения дегенеративных заболеваний RU2496790C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07018131A EP2036921A1 (en) 2007-09-14 2007-09-14 Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP07018131.8 2007-09-14
EP08006810 2008-04-03
EP08006810.9 2008-04-03
PCT/EP2008/007579 WO2009033715A2 (en) 2007-09-14 2008-09-12 Neuroendocrine factors for treatment of degenerative diseases

Publications (2)

Publication Number Publication Date
RU2010114713A RU2010114713A (ru) 2011-10-20
RU2496790C2 true RU2496790C2 (ru) 2013-10-27

Family

ID=40452588

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010114713/10A RU2496790C2 (ru) 2007-09-14 2008-09-12 Нейроэндокринные факторы для лечения дегенеративных заболеваний

Country Status (13)

Country Link
US (1) US20110002972A1 (cg-RX-API-DMAC7.html)
EP (1) EP2212344B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010539123A (cg-RX-API-DMAC7.html)
KR (1) KR20100075493A (cg-RX-API-DMAC7.html)
CN (1) CN101821283A (cg-RX-API-DMAC7.html)
AU (1) AU2008297889A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816784A8 (cg-RX-API-DMAC7.html)
CA (1) CA2699411A1 (cg-RX-API-DMAC7.html)
MX (1) MX2010002716A (cg-RX-API-DMAC7.html)
NZ (1) NZ583851A (cg-RX-API-DMAC7.html)
RU (1) RU2496790C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009033715A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201001644B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1400024B1 (it) * 2010-05-21 2013-05-17 Uni Politecnica Delle Marche Uso farmaceutico di semaforine.
UY33833A (es) * 2010-12-23 2012-07-31 Sanofi Sa Proteína de fusión Robo1-Fc para su uso en el tratamiento del hepatocarcinoma
ES3013463T3 (en) * 2011-07-04 2025-04-14 Mesoblast Inc Treating or preventing rheumatic disease
CN104582727B (zh) * 2012-06-15 2018-04-27 财团法人峩山社会福祉财团 利用Slit-Robo系统用于预防或治疗骨折或骨质疏松症的组合物
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119445A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119447A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
WO2015072527A1 (ja) * 2013-11-13 2015-05-21 国立大学法人大阪大学 ネトリン１含有破骨細胞形成抑制剤
HUE068789T2 (hu) 2014-03-14 2025-01-28 Univ New York State Res Found A csontnövekedés és a csontlebontás neurogén szabályozása
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US20200397860A1 (en) * 2018-02-14 2020-12-24 Cornell University Slit and bone growth modulation
KR102353524B1 (ko) * 2019-02-27 2022-01-20 주식회사 대웅제약 알부민이 결합된, Slit3 단백질의 LRRD2를 포함하는 골 관련 질환 예방 또는 치료용 조성물
US20220340643A1 (en) * 2019-09-13 2022-10-27 Rutgers, The State University Of New Jersey Aav-compatible laminin-linker polymerization proteins
CN110841057B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎巴布膏剂中的应用
CN110721308B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种用于治疗骨关节炎的药物复方制剂及其制备方法
CN110772632B (zh) * 2019-11-19 2023-08-11 四川大学华西医院 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
CN110694051B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用
CN110711244B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
CN110684805B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
US20240277861A1 (en) * 2021-07-26 2024-08-22 Purotech Bio, Inc. Anti-hepatitis b virus agent targeting host factor lipg

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055321A2 (en) * 1999-03-17 2000-09-21 Washington University Vertebrate protein slit, dna sequence encoding it and uses thereof
WO2002006315A2 (en) * 2000-07-18 2002-01-24 Compugen Ltd. Novel nucleic acid and amino acid sequences
WO2002010217A2 (en) * 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
RU2221563C2 (ru) * 1993-01-07 2004-01-20 Авентис Фарма С.А. Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
WO2005074556A2 (en) * 2004-01-30 2005-08-18 The General Hospital Corporation Netrin compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1116490A (ja) * 1997-06-26 1999-01-22 Kyocera Corp プラズマディスプレイパネル用隔壁の製造方法及びプラズマディスプレイパネル用基板
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6342370B1 (en) * 1997-10-31 2002-01-29 Osiris Therapeutics, Inc. Human slit polypeptide and polynucleotides encoding same
JPH11164690A (ja) * 1997-12-05 1999-06-22 Asahi Chem Ind Co Ltd 脊椎動物スリット蛋白質
US6924355B2 (en) * 1998-09-01 2005-08-02 Genentech, Inc. PRO1343 polypeptides
WO2002012346A2 (en) * 2000-08-10 2002-02-14 Pharmacia Corporation A new slit-like protein obtained from a cdna library from hs-5 stromal cell line
US20050014680A1 (en) * 2003-04-15 2005-01-20 Crabtree Gerald R. Methods and compositions for enhancing neuron growth and survival
BRPI0720038A2 (pt) * 2006-12-11 2013-12-24 Univ Utah Res Found Métodos para inibir a permeabilidade vascular em tecido, para triar ou avaliar um agente que inibe a permeabilidade vascular, para tratar ou prevenir a síndrome da angústia respiratória, a retinopatia de prematuridade, a retinopatia diabética e a degeneração macular úmida em um indivíduo, para tratar indivíduos com sugestões repulsivas ou miméticos e para promover a angiogênese em um tecido, polipeptídeo isolado, ácido nucleico isolado, e, vetor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2221563C2 (ru) * 1993-01-07 2004-01-20 Авентис Фарма С.А. Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
WO2000055321A2 (en) * 1999-03-17 2000-09-21 Washington University Vertebrate protein slit, dna sequence encoding it and uses thereof
WO2002006315A2 (en) * 2000-07-18 2002-01-24 Compugen Ltd. Novel nucleic acid and amino acid sequences
WO2002010217A2 (en) * 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
WO2005074556A2 (en) * 2004-01-30 2005-08-18 The General Hospital Corporation Netrin compositions and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LITTLE M.H. ET al. Dual trafficking of Slit3 to mitochondria and cell surface demonstrates novel localization for Slit protein, Am J Physiol Cell Physiol, 2011, v. 281, no. 2, pp.486-495. *
LITTLE M.H. ET al. Dual trafficking of Slit3 to mitochondria and cell surface demonstrates novel localization for Slit protein, Am J Physiol Cell Physiol, 2011, v. 281, no. 2, pp.486-495. МАРРИ Р. и др. Биохимия человека. - М.: МИР, 1993, с.34. *
МАРРИ Р. и др. Биохимия человека. - М.: МИР, 1993, с.34. *

Also Published As

Publication number Publication date
BRPI0816784A8 (pt) 2016-01-19
MX2010002716A (es) 2010-07-05
EP2212344A2 (en) 2010-08-04
AU2008297889A1 (en) 2009-03-19
CA2699411A1 (en) 2009-03-19
NZ583851A (en) 2012-06-29
WO2009033715A2 (en) 2009-03-19
KR20100075493A (ko) 2010-07-02
ZA201001644B (en) 2011-03-30
JP2010539123A (ja) 2010-12-16
EP2212344B1 (en) 2014-03-26
RU2010114713A (ru) 2011-10-20
BRPI0816784A2 (pt) 2015-03-24
CN101821283A (zh) 2010-09-01
US20110002972A1 (en) 2011-01-06
WO2009033715A3 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
RU2496790C2 (ru) Нейроэндокринные факторы для лечения дегенеративных заболеваний
US6924367B2 (en) Method of modulating tissue growth using Frzb Protein
EP3520804A1 (en) Composition for cartilage
JP2010520212A (ja) 骨石灰化を増進するｎｅｌｌ−１
KR100898765B1 (ko) 성장인자 복합체
JP2006502971A (ja) 結合組織刺激ペプチド
BR122016021558A2 (pt) Polipeptídeos isolados, seus usos, e composição farmacêutica
JP2004504354A (ja) 非タンパク質分解的活性化トロンビンレセプターのアゴニストによる軟骨成長の刺激
EP1261365A1 (en) Product and method for biological anchoring of connective tissue to bone
US20250345393A1 (en) Isoform nell-1 peptide
KR20150013455A (ko) 골 수복 촉진제
US20110033516A1 (en) Methods and compositions for bone healing by periostin
WO2007044396A2 (en) Fibronectin polypeptides and methods of use
EP2036921A1 (en) Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
KR20160109561A (ko) 관절염 예방 또는 치료용 약학적 조성물
US6884871B2 (en) Isolation and use of tissue growth-inducing Frzb protein
US7049291B2 (en) Isolation and method of using tissue growth-inducing Frzb protein
WO2019246013A1 (en) Peptides to enhance bone growth, repair and cell function
WO2010135915A1 (zh) 中期因子蛋白的用途及含该蛋白的医用装置
WO2008077938A1 (en) Modulators of talin/integrin association and use thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140913